The Fort Worth Press - Asia-Pacific gets new weapon in fight against drug-resistant TB

USD -
AED 3.672504
AFN 64.503991
ALL 81.720038
AMD 360.406323
ANG 1.790403
AOA 918.000367
ARS 1568.130552
AUD 1.4997
AWG 1.8025
AZN 1.70397
BAM 1.781807
BBD 2.01075
BDT 124.174373
BGN 1.77347
BHD 0.376714
BIF 3006.969435
BMD 1
BND 1.287933
BOB 11.65581
BRL 5.949504
BSD 0.998315
BTN 92.467544
BWP 14.234045
BYN 2.99713
BYR 19600
BZD 2.007835
CAD 1.43465
CDF 2280.000362
CHF 0.840443
CLF 0.025921
CLP 1017.646791
CNY 6.67775
CNH 6.682804
COP 3427.686421
CRC 446.863754
CUC 1
CUP 23.960279
CVE 100.455519
CZK 22.299704
DJF 177.779802
DKK 6.814905
DOP 60.22867
DZD 136.148135
EGP 53.415023
ERN 15
ETB 163.858971
EUR 0.91135
FJD 2.29155
FKP 0.764421
GBP 0.764526
GEL 2.603861
GGP 0.764421
GHS 11.755113
GIP 0.764421
GMD 74.000355
GNF 8850.726552
GTQ 7.630848
GYD 208.864392
HKD 7.83895
HNL 26.834601
HRK 6.831965
HTG 130.916048
HUF 340.290388
IDR 18292.95
ILS 3.34105
IMP 0.764421
INR 92.680504
IQD 1513.506127
IRR 1937364.503816
ISK 125.110386
JEP 0.764421
JMD 158.14695
JOD 0.70904
JPY 158.55504
KES 129.831914
KGS 87.450384
KHR 4073.247392
KMF 449.00035
KPW 900.00035
KRW 1345.905039
KWD 0.31178
KYD 0.831959
KZT 455.400173
LAK 22505.352344
LBP 89404.637179
LKR 332.009293
LRD 167.220881
LSL 17.451373
LTL 2.95274
LVL 0.60489
LYD 6.459254
MAD 9.983601
MDL 18.299094
MGA 4524.210814
MKD 56.078896
MMK 2100.280273
MNT 3608.279079
MOP 8.060128
MRU 40.693299
MUR 46.780378
MVR 15.403739
MWK 1731.152918
MXN 19.15845
MYR 4.113039
MZN 63.903729
NAD 17.451373
NGN 1355.000344
NIO 36.742131
NOK 9.76155
NPR 147.947889
NZD 1.828655
OMR 0.381679
PAB 0.998315
PEN 3.426958
PGK 4.494147
PHP 64.018038
PKR 275.965381
PLN 4.06445
PYG 6295.267162
QAR 3.649342
RON 4.877804
RSD 107.165308
RUB 81.477338
RWF 1474.878149
SAR 3.751806
SBD 8.124013
SCR 13.994038
SDG 601.503676
SEK 10.228904
SGD 1.289404
SHP 0.764263
SLE 22.850371
SLL 20969.503664
SOS 570.582608
SRD 37.363504
STD 20697.981008
STN 22.320412
SVC 8.735025
SYP 13002.000337
SZL 17.447274
THB 34.045038
TJS 9.179702
TMT 3.5
TND 3.023915
TOP 2.40776
TRY 50.538804
TTD 6.776295
TWD 32.969604
TZS 2663.052886
UAH 44.835512
UGX 4218.102309
UYU 40.595818
UZS 11951.897235
VES 917.61775
VND 25801.5
VUV 120.826687
WST 2.823281
XAF 597.806686
XAG 0.024398
XAU 0.00028370404
XCD 2.70255
XCG 1.799299
XDR 0.707052
XOF 597.806686
XPF 108.650298
YER 236.603589
ZAR 17.61858
ZMK 9001.203584
ZMW 20.555733
ZWL 321.999592
SSP 5775.741752
MXV 2.147601
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Asia-Pacific gets new weapon in fight against drug-resistant TB
Asia-Pacific gets new weapon in fight against drug-resistant TB / Photo: © AFP

Asia-Pacific gets new weapon in fight against drug-resistant TB

A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.

Text size:

The region had most of the world's estimated 10.6 million new TB cases in 2022, and more than half of the 1.3 million deaths, World Health Organization (WHO) figures show.

While TB can be successfully treated with antibiotics, more than three percent of new TB patients are resistant to commonly prescribed drugs.

Until recently, treatment for these patients involved daily painful injections or a fistful of pills for 18 months or longer, while some endured severe side effects such as nausea and, in extreme cases, blindness.

Many people prematurely quit their treatment, which had a success rate of 63 percent or lower.

Now, a new drug regimen involving fewer pills and side effects is being rolled out in the Asia-Pacific, including the Philippines, Vietnam and Indonesia, where trials have shown a more than 90 percent cure rate after six months.

The treatment, known as BPaL, combines the antibiotics bedaquiline, pretomanid and linezolid, and has received regulatory approval in more than 60 countries since 2019, according to the non-profit TB Alliance, which developed it.

The WHO updated its guidelines in 2022 to allow BPaL to be used with or without a fourth antibiotic called moxifloxacin.

BPaL has been life-changing for Filipino cook Efifanio Brillante, who was diagnosed with drug-resistant TB in June 2022 and initially went on an older form of treatment.

Brillante, 57, was swallowing 20 tablets a day, but it left him feeling so nauseous that he couldn't work or eat.

He stopped the medication after two weeks even though he knew the decision could be fatal.

"It's very difficult. You're always in bed," Brillante told AFP about his experience of having TB.

"Sometimes I couldn't even breathe."

The following month, Brillante joined a BPaL trial at the Jose B Lingad Memorial General Hospital in Pampanga province, north of the Philippine capital Manila.

He took between three and seven pills a day and was cured after six months.

"I'm very thankful that I was healed," Brillante told AFP in his home.

"If I didn't take that BPaL, I might already be buried in the cemetery."

- 'A curable disease' -

TB, once called consumption, is caused by a bacteria that primarily attacks the lungs and is transmitted through the air by infected people, for example by coughing.

While it is found in every country, poorer people living and working in overcrowded conditions are at higher risk of the disease.

Eight countries accounted for two-thirds of new TB cases in 2022: India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and the Democratic Republic of Congo.

One of the biggest challenges of treating drug-resistant TB has been getting patients to take the full course of their medication.

Even in countries where treatment is free, patients face crippling travel costs to hospitals and loss of income, or even their job, due to the illness and side-effects of the drugs, leading many to stop taking their pills.

In Vietnam, most people diagnosed with TB are from low-income families, Hoang Thi Thanh Thuy from the Vietnam National Tuberculosis Program told AFP.

Nearly everyone with drug-resistant TB endured "catastrophic" expenses over the period of their treatment, she said.

"All of these difficulties can affect patient compliance and lead to poor treatment and increasing drug resistance," Thuy said.

Identifying people with TB is also a challenge.

In Indonesia, some healthcare facilities are still not able to properly diagnose the disease, said Imran Pambudi of the health ministry.

Fear of social stigma from a positive diagnosis is also common.

"We're trying to educate them that TB is a curable disease," said Irene Flores, who led the BPaL trial at the Jose B Lingad Memorial General Hospital in the Philippines.

"If they come early, we can prevent complications."

- More investment needed -

After years of decline, the number of people falling ill with TB and drug-resistant tuberculosis began increasing during the Covid-19 pandemic, which disrupted diagnosis and treatment, the WHO said previously.

After gargantuan global efforts to develop a vaccine against the coronavirus, the WHO has called for increased funding to fight TB.

"As TB stopped being a high income-country problem, motivation to invest in research and development for new TB drugs dried up," said Sandeep Juneja, senior vice president of market access at the TB Alliance.

To help accelerate the rollout of BPaL, with or without moxifloxacin, the TB Alliance has set up a "knowledge hub" in Manila to provide training and assistance to other countries.

In India, where BPaL has been approved, there is growing impatience for it to be introduced into health clinics given the country's world-beating caseload.

"BPaL should be rolled out soon because it will spare patients a lot of headaches and provide psychological relief too, besides reducing cost of treatment in the long run," said Ravikant Singh, founder of advocacy group Doctors For You.

Juneja said the new regimen meant treating drug-resistant TB was no longer a guessing game of whether a patient would survive or not.

But more is needed to be done, he added.

"I hope this is... just the beginning of a new era of TB treatment where they will be even simpler, even shorter."

burs-pam/amj/dhw/jfx

J.P.Estrada--TFWP